Targeted therapies in gynaecological cancers

• Published in: Histopathology 2020-01, Vol.76 (1), p.157-170
• Main Authors: Crusz, Shanthini M, Miller, Rowan E
• Format: Article
• Language: English
• Subjects: Angiogenesis; anti‐angiogenesis; Cancer therapies; Cervical cancer; Cervix; Chemotherapy; Deoxyribonucleic acid; DNA; DNA biosynthesis; DNA repair; Drug delivery; Endometrium; Genomics; gynaecological cancers; Gynecology; HPV; Human papillomavirus; immune check‐point inhibitors; Immunosuppressive agents; Mismatch repair; Mitosis; Monoclonal antibodies; Ovarian cancer; PARP; PD-L1 protein; Poly(ADP-ribose) polymerase; Precision medicine; Signal transduction; Stroma; targeted therapy; Tumors
• ISSN: 0309-0167; 1365-2559
• DOI: 10.1111/his.14009

The treatment of cancer has changed dramatically over the last decade, driven by increased understanding of the cancer genome, immune landscape, molecular alterations and aberrant pathways that drive cancer progression. Advances in molecular biology have led to the development of targeted agents, including monoclonal antibodies, small molecules and check‐point inhibitors. Unlike chemotherapy, which inhibits DNA replication and mitosis, these agents target cancer signalling pathways, stroma, immune microenvironment and vasculature in tumour tissues. In gynaecological cancer, drugs targeting defective DNA repair, such as PARP inhibitors, have been approved for advanced ovarian cancer, and drugs targeting angiogenesis have been used in the treatment of advanced or recurrent ovarian and cervical cancers. Immune check‐point inhibitors such as anti‐PD‐1/PD‐L1 antibodies have proved successful for mismatch repair‐deficient endometrial cancers and HPV‐targeted therapies are under development for HPV‐related malignancies. In this era of precision medicine, improved understanding of cancer biology and genomics needs to be utilised to develop predictive biomarkers for these targeted therapies to maximise patient benefit.